Human Varicella-Zoster Immunoglobulin - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510242658

Publication Date:

October 17, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Human varicella-zoster immune globulin is a solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections.
The global market for Human Varicella-Zoster Immunoglobulin was estimated to be worth US$ 159 million in 2023 and is forecast to a readjusted size of US$ 201.1 million by 2030 with a CAGR of 3.4% during the forecast period 2024-2030
Herpes zoster is an acute herpetic viral skin disease caused by the varicella-zoster virus that involves the nerves and skin. Infected individuals treated with human water were less likely to develop severe varicella-zoster virus than those not treated with it.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Varicella-Zoster Immunoglobulin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Varicella-Zoster Immunoglobulin by region & country, by Type, and by Application.
The Human Varicella-Zoster Immunoglobulin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Varicella-Zoster Immunoglobulin.
麻豆原创 Segmentation
By Company
Bio Products Laboratory
MassBiologics
Saol Therapeutics
Aptevo Biotherapeutics Llc
Ki Biopharma Llc
Cangene Biopharma
Kamada
Salmedon
Segment by Type:
Freeze-dried Powder
Injection
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Varicella-Zoster Immunoglobulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Human Varicella-Zoster Immunoglobulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Human Varicella-Zoster Immunoglobulin in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Human Varicella-Zoster Immunoglobulin Product Introduction
1.2 Global Human Varicella-Zoster Immunoglobulin 麻豆原创 Size Forecast
1.2.1 Global Human Varicella-Zoster Immunoglobulin Sales Value (2019-2030)
1.2.2 Global Human Varicella-Zoster Immunoglobulin Sales Volume (2019-2030)
1.2.3 Global Human Varicella-Zoster Immunoglobulin Sales Price (2019-2030)
1.3 Human Varicella-Zoster Immunoglobulin 麻豆原创 Trends & Drivers
1.3.1 Human Varicella-Zoster Immunoglobulin Industry Trends
1.3.2 Human Varicella-Zoster Immunoglobulin 麻豆原创 Drivers & Opportunity
1.3.3 Human Varicella-Zoster Immunoglobulin 麻豆原创 Challenges
1.3.4 Human Varicella-Zoster Immunoglobulin 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Human Varicella-Zoster Immunoglobulin Players Revenue Ranking (2023)
2.2 Global Human Varicella-Zoster Immunoglobulin Revenue by Company (2019-2024)
2.3 Global Human Varicella-Zoster Immunoglobulin Players Sales Volume Ranking (2023)
2.4 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Company Players (2019-2024)
2.5 Global Human Varicella-Zoster Immunoglobulin Average Price by Company (2019-2024)
2.6 Key Manufacturers Human Varicella-Zoster Immunoglobulin Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Human Varicella-Zoster Immunoglobulin Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Human Varicella-Zoster Immunoglobulin
2.9 Human Varicella-Zoster Immunoglobulin 麻豆原创 Competitive Analysis
2.9.1 Human Varicella-Zoster Immunoglobulin 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Human Varicella-Zoster Immunoglobulin Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Varicella-Zoster Immunoglobulin as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Freeze-dried Powder
3.1.2 Injection
3.2 Global Human Varicella-Zoster Immunoglobulin Sales Value by Type
3.2.1 Global Human Varicella-Zoster Immunoglobulin Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Human Varicella-Zoster Immunoglobulin Sales Value, by Type (2019-2030)
3.2.3 Global Human Varicella-Zoster Immunoglobulin Sales Value, by Type (%) (2019-2030)
3.3 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Type
3.3.1 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Human Varicella-Zoster Immunoglobulin Sales Volume, by Type (2019-2030)
3.3.3 Global Human Varicella-Zoster Immunoglobulin Sales Volume, by Type (%) (2019-2030)
3.4 Global Human Varicella-Zoster Immunoglobulin Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.2 Global Human Varicella-Zoster Immunoglobulin Sales Value by Application
4.2.1 Global Human Varicella-Zoster Immunoglobulin Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Human Varicella-Zoster Immunoglobulin Sales Value, by Application (2019-2030)
4.2.3 Global Human Varicella-Zoster Immunoglobulin Sales Value, by Application (%) (2019-2030)
4.3 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Application
4.3.1 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Human Varicella-Zoster Immunoglobulin Sales Volume, by Application (2019-2030)
4.3.3 Global Human Varicella-Zoster Immunoglobulin Sales Volume, by Application (%) (2019-2030)
4.4 Global Human Varicella-Zoster Immunoglobulin Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Human Varicella-Zoster Immunoglobulin Sales Value by Region
5.1.1 Global Human Varicella-Zoster Immunoglobulin Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Human Varicella-Zoster Immunoglobulin Sales Value by Region (2019-2024)
5.1.3 Global Human Varicella-Zoster Immunoglobulin Sales Value by Region (2025-2030)
5.1.4 Global Human Varicella-Zoster Immunoglobulin Sales Value by Region (%), (2019-2030)
5.2 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Region
5.2.1 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Region (2019-2024)
5.2.3 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Region (2025-2030)
5.2.4 Global Human Varicella-Zoster Immunoglobulin Sales Volume by Region (%), (2019-2030)
5.3 Global Human Varicella-Zoster Immunoglobulin Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
5.4.2 North America Human Varicella-Zoster Immunoglobulin Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
5.5.2 Europe Human Varicella-Zoster Immunoglobulin Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
5.6.2 Asia Pacific Human Varicella-Zoster Immunoglobulin Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
5.7.2 South America Human Varicella-Zoster Immunoglobulin Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
5.8.2 Middle East & Africa Human Varicella-Zoster Immunoglobulin Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Human Varicella-Zoster Immunoglobulin Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Human Varicella-Zoster Immunoglobulin Sales Value
6.2.1 Key Countries/Regions Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
6.2.2 Key Countries/Regions Human Varicella-Zoster Immunoglobulin Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
6.3.2 United States Human Varicella-Zoster Immunoglobulin Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Human Varicella-Zoster Immunoglobulin Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
6.4.2 Europe Human Varicella-Zoster Immunoglobulin Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Human Varicella-Zoster Immunoglobulin Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
6.5.2 China Human Varicella-Zoster Immunoglobulin Sales Value by Type (%), 2023 VS 2030
6.5.3 China Human Varicella-Zoster Immunoglobulin Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
6.6.2 Japan Human Varicella-Zoster Immunoglobulin Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Human Varicella-Zoster Immunoglobulin Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
6.7.2 South Korea Human Varicella-Zoster Immunoglobulin Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Human Varicella-Zoster Immunoglobulin Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
6.8.2 Southeast Asia Human Varicella-Zoster Immunoglobulin Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Human Varicella-Zoster Immunoglobulin Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Human Varicella-Zoster Immunoglobulin Sales Value, 2019-2030
6.9.2 India Human Varicella-Zoster Immunoglobulin Sales Value by Type (%), 2023 VS 2030
6.9.3 India Human Varicella-Zoster Immunoglobulin Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bio Products Laboratory
7.1.1 Bio Products Laboratory Company Information
7.1.2 Bio Products Laboratory Introduction and Business Overview
7.1.3 Bio Products Laboratory Human Varicella-Zoster Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Bio Products Laboratory Human Varicella-Zoster Immunoglobulin Product Offerings
7.1.5 Bio Products Laboratory Recent Development
7.2 MassBiologics
7.2.1 MassBiologics Company Information
7.2.2 MassBiologics Introduction and Business Overview
7.2.3 MassBiologics Human Varicella-Zoster Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
7.2.4 MassBiologics Human Varicella-Zoster Immunoglobulin Product Offerings
7.2.5 MassBiologics Recent Development
7.3 Saol Therapeutics
7.3.1 Saol Therapeutics Company Information
7.3.2 Saol Therapeutics Introduction and Business Overview
7.3.3 Saol Therapeutics Human Varicella-Zoster Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Saol Therapeutics Human Varicella-Zoster Immunoglobulin Product Offerings
7.3.5 Saol Therapeutics Recent Development
7.4 Aptevo Biotherapeutics Llc
7.4.1 Aptevo Biotherapeutics Llc Company Information
7.4.2 Aptevo Biotherapeutics Llc Introduction and Business Overview
7.4.3 Aptevo Biotherapeutics Llc Human Varicella-Zoster Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Aptevo Biotherapeutics Llc Human Varicella-Zoster Immunoglobulin Product Offerings
7.4.5 Aptevo Biotherapeutics Llc Recent Development
7.5 Ki Biopharma Llc
7.5.1 Ki Biopharma Llc Company Information
7.5.2 Ki Biopharma Llc Introduction and Business Overview
7.5.3 Ki Biopharma Llc Human Varicella-Zoster Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Ki Biopharma Llc Human Varicella-Zoster Immunoglobulin Product Offerings
7.5.5 Ki Biopharma Llc Recent Development
7.6 Cangene Biopharma
7.6.1 Cangene Biopharma Company Information
7.6.2 Cangene Biopharma Introduction and Business Overview
7.6.3 Cangene Biopharma Human Varicella-Zoster Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Cangene Biopharma Human Varicella-Zoster Immunoglobulin Product Offerings
7.6.5 Cangene Biopharma Recent Development
7.7 Kamada
7.7.1 Kamada Company Information
7.7.2 Kamada Introduction and Business Overview
7.7.3 Kamada Human Varicella-Zoster Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Kamada Human Varicella-Zoster Immunoglobulin Product Offerings
7.7.5 Kamada Recent Development
7.8 Salmedon
7.8.1 Salmedon Company Information
7.8.2 Salmedon Introduction and Business Overview
7.8.3 Salmedon Human Varicella-Zoster Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Salmedon Human Varicella-Zoster Immunoglobulin Product Offerings
7.8.5 Salmedon Recent Development
8 Industry Chain Analysis
8.1 Human Varicella-Zoster Immunoglobulin Industrial Chain
8.2 Human Varicella-Zoster Immunoglobulin Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Human Varicella-Zoster Immunoglobulin Sales Model
8.5.2 Sales Channel
8.5.3 Human Varicella-Zoster Immunoglobulin Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Bio Products Laboratory
MassBiologics
Saol Therapeutics
Aptevo Biotherapeutics Llc
Ki Biopharma Llc
Cangene Biopharma
Kamada
Salmedon

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.